Main Article Content
have limited applicability, especially when the drugs are poorly soluble simultaneously in aqueous and in non-aqueous media. Nanosuspension technology can be used to improve the stability as well as the bioavailability of poorly soluble
drugs. Nanosuspensions are biphasic systems consisting of pure drug particles dispersed in an aqueous vehicle, stabilized by surfactants. These are simple to prepare and are more advantageous than other approaches. Techniques such as wet milling, high-pressure homogenization, emulsificationâ€“solvent evaporation and super critical fluid have been used in the preparation of nanosuspensions. It has the advantage of delivery by various routes, including oral, parenteral, pulmonary and ocular routes. The present article reviews the current methods used to prepare nanosuspensions and their application in drug delivery.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
The Biopharmaceutics Classification System (BCS) Guidance, Office of
Pharmaceutical Science. Available from: http://www.fda.gov/cder/OPS/
BCS_guidance.htm [last accessed on 2008 Jan 12].
Clewlow PJ. Survival of the smartest. Scripâ€™s Target world drug delivery
Seedher N, Kaur J. Solubilization of nimesulide; use of co-solvents. IJPS
Mersiko-Liversidge E, MGurk SL, Liversidge GG. Insulin nanoparticles:
A novel formulation approach for poorly water soluble Zn-Insulin.
Pharm Res 2004;21:1545-53.
Benjamin C-Y Lu, Dingan Zang, Wei Sheng. Solubility enhancement in
supercritical fluids. Pure and Appl Chem 1990;62:2277-85.
Abu T. M. Serajuddin. Solid dispersion of poorly soluble drugs-Early
promises, subsequent problems, and recent breakthroughs. J Pharm
FrÃ¶mming KH. Cyclodextrine-eine vielseitig verwendbare Gruppe neuer
Hilfsstioffe. In: Muller RH, Hildebrand GE, editors. Pharmazeutische
Technologie; Modern Arzneiformen, 2nd ed. Stuttgart: WVG; 1998.
Sucker H. Hydrosole, eine Alternative fÃ¼r die parenterale Anwendung
von schwer wasserloslichen Wirkstoffen. In: Muller RH, Hildebrand GE,
editors. Pharmazeutische Technologie; Modern Arzneiformen. 2nd ed.
Stuttgart: WVG; 1998.
Dubey R. Pure drug nanosuspensions-Impact of nanosuspension technology on drug discovery and development. Drug Del Tech 2006;6:65-71.
Muller RH Peters K, Becker R, Kruss B. Nanosuspension for IV
administration of poorly soluble drugs-Stability during sterilization and
long term storage. Proc Int Symp Control Rel Bioact Mater 1995;22:574-5.
MÃ¼ller RH, Grau MJ, Hildebrand GE. Increase of solubility of poorly
soluble drugs by transfer to Dissocubes using high pressure
homogenization. Proc Int Symp Control Rel Bioact Mater 1999;26:112-3.
SchÃ¶ler N, Krause K, Kayser O, MÃ¼ller RH, Borner K, Hahn H, et al.
Atovaquone nanosuspensions show excellent therapeutic effect in a
new murine model of reactivated toxoplamosis. Antimicrob Agents
Radtke M. Nanopure: pure drug nanoparticles for the formulation of
poorly soluble drugs. New Drugs 2001;3:62-8.
Dearns R. Atovaquone pharmaceutical compositions. US Patent US
Young TJ, Mawson S, Johnston KP, Henriska IB, Pace GW, Mishra AK.
Rapid expansion from supercritical to aqueous solution to produce
submicron suspension of water insoluble drugs. Biotechnol Prog
Chattopadhyay P, Gupta RP. Production of griseofulvin nanoparticles
using supercritical CO2 antisolvent with enhanced mass transfer. Int
J Pharm 2001;228:19-31.
Bohm BH, Muller RH. Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. PSTT 1999;2:336-9.
Muller RH, Becker R, Kross B, Peters K. United States Patent No.5858410.January 12, 1999.
Setler P. Identifying new oral technologies to meet your drug delivery
needs for the delivery of peptides and proteins and poorly soluble
molecules. IIR Limited, Drug delivery systems London: 1999.
Liversidge GC. Paper presented at the 23rd International symposium
of the Controlled Release Bioactive Materials Society. Workshop on
Particulate Drug Delivery Systems; 1996.
Kayser O, Olbrich C, Yardley V, Kiderten Ap, Croft SL. Formulation of
amphotericin-B as nanosuspension for oral administration. Int J Pharm
Chen Y, Liu J, Yang X, Zhao X, Xu H. Oleanolic acid nanosuspensions:
Preparation, in vitro characterization and enhanced hepato protective
effect. J Pharm Pharmacol 2005;57:259-64.
Kocbek P, Baumgartner S, Kristi J. Preparation and evaluation of
nanosuspensions for enhancing dissolution of poorly soluble drugs.
Int J Pharm 2006;312:179-86.
Langutth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T, et al.
Nanosuspension formulation for low soluble drugs: Pharmacokinetics
evaluation using spiranolactone as model compound. Drug
Dev Ind Pharm 2005;31:319-29,
Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, MÃ¼ller RH, et al.
Preparation of a clofazimine nanosuspensions for intravenous use and
evaluation of its therapeutic efficacy in murine mycobacterium avium
infection. J Antimicrob Chemother 2000;45:77-83.
Jacobs C, Kayder O, Muller RH. Nanosuspensions as a new approach for the
formulation of poorly soluble drug tarazepide. Int J Pharm 2000;196:161-4.
Moschwitzer J, Achleitner G, Promper H, Muller RH. Development of
an intravenously injectable chemically stable aqueous omeprazole
formulation using nanosuspension technology. Eur J Pharm Biopharm
Muller RH, Jacobs C. Production and Characterization of Budenoside
nanosuspension for pulmonar y administration. Pharm Res
Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G.
Preparation and characterization of Eudragit retard nanosuspensions
for the ocular delivery of cloricromene. AAPS Pharmscitech
Kayser O, Lemke A, Hernandz.Trejo N. The impact of Nanobiotechnology on the development of new drug delivery systems. Current Pharm Biotech 2005;6:3-5.
Shah T, Patel D, Hirani J, Amin AF. Nanosuspensions as a drug delivery
systems-A comprehensice review. Drug Del Tech 2007;7:42-53.
Kayser O. Nanosuspensions for the formulation of aphidicolin
to improve drug targeting effects against Leishmania infected
macrophages. Int J Pharm 2000;196:253-6.
Ponchel G, Montisci MJ, Dembri A, Durrer C, DuchÃªne. D. Mucoadhesion of colloidal particulate systems in the gastrointestinal tract. Eur J Pharm Biopharm 1997; 44:25-31.
Kayser O. A new approach for targeting to Cryptosporidium parvum
using mucoadhesive nanosuspensions: research and applications.
Int J Pharm 2001;214:83-5.